Proprietary spearmint extract, Neumentix, granted European patent for promoting neurogenesis
The patent (number EP 3 538 085 B1) was granted on July 12, 2023, and was validated in Spain, France, Germany, Italy, the Netherlands, and the United Kingdom.
Photo © Shutterstock.com/jovan vitanovski
Kemin Industries (Des Moines, IA) has announced that it was granted a patent by the European Patent Office for its proprietary spearmint extract called Neumentix. The patent (number EP 3 538 085 B1) was granted on July 12, 2023, and was validated in Spain, France, Germany, Italy, the Netherlands, and the United Kingdom. The fourth patent filed and granted for the ingredient; it pertains to the ability of the extract to promote the growth of neurons.
The polyphenol-rich extract contains over 50 phenolic compounds, including rosmarinic, salvianolic and lithospermic acids. According to Kemin, Neumentix targets the hippocampus, promoting neurogenesis to supporting one’s ability to learn, manage information, and react.
“Our research has indicated that Neumentix, sourced from patented plants and characterized by its phenolic complex, works to nourish the neurons in the brain and may increase new neural growth in specific areas of the brain, providing an important source of neuronutrition to fuel brain performance in healthy adults.” said Brenda Fonseca, global technical services lead, Kemin Human Nutrition and Health, in a press release. Fonseca is also an inventor listed on the patent.
"Backed by over 19 peer-reviewed scientific publications covering clinical and preclinical research, as well as spearmint plant features, Neumentix is a great choice for manufacturers looking to formulate with safe, sustainable and scientifically backed brain health ingredients to help promote new neuronal growth,” added Fonseca.
What's next for NPA and CRN in their complaints against New York state?
May 2nd 2024The latest updates in the efforts of the Natural Products Association and the Council for Responsible Nutrition to sue New York state for its law banning the sale of weight management and muscle building supplements to minors.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
